Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis

• Published in: Caspian journal of internal medicine 2020-01, Vol.11 (2), p.124-134
• Main Authors: Ebrahimi, Parvin, Farhadi, Zeynab, Behzadifar, Masoud, Shabaninejad, Hosein, Abolghasem Gorji, Hassan, Taheri Mirghaed, Masood, Salemi, Morteza, Amin, Kamyar, Mohammadibakhsh, Roghayeh, Bragazzi, Nicloa Luigi, Sohrabi, Rahim
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2008-6164; 2008-6172
• DOI: 10.22088/cjim.11.2.124

Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the healthcare systems facing this very challenging issue. Aspirin continues to be the major gold-standard treatment worldwide in the prevention of thrombotic disease in patients with CVD, even though not all individuals respond to antiplatelet therapy in a similar way, being resistant to aspirin. The aim of this study was to determine the prevalence of laboratory defined aspirin resistance in CVD patients worldwide. Relevant articles were identified through searching EMBASE, PubMed/ MEDLINE, ISI /Web of Science, Scopus, and the Cochrane Library, from January 2000 to February 2018. The methodological quality of the included studies was critically appraised using the Newcastle-Ottawa scale. The pooled prevalence of laboratory defined aspirin resistance was computed using the Der Simonian-Laird random-effect model. We included 65 studies, with a total of 10,729 patients. The overall prevalence of laboratory defined aspirin resistance in CVD patients was 24.7% ([95%CI 21.4-28.4]. Women were found to be at increased risk of laboratory defined aspirin resistance compared to men, with an odds ratio of 1.16 [95%CI 0.87-1.54]. Doctors and healthcare providers should pay special attention to aspirin resistance since lack of awareness could cause problems and increase mortality in these patients, if not properly treated with higher aspirin doses.